Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Randomized Clinical Trial in Patients With a Pedophilic Disorder

A Randomized Clinical Trial in Patients With a Pedophilic Disorder Opinion EDITORIAL A Milestone Peer Briken, MD Nowadays, experts distinguish very clearly between pedo- terone (MPA) acetate is an option. For the high-risk groups, philic disorder as a psychiatric disorder (characterized by gonadotropin-releasing hormone (GnRH) agonists, such as leu- prolide, have been in use for more than 20 years. However, for intense sexual interest in children accompanied by distress, interpersonal difficulty, and/or a risk of sexual offenses against SSRIs as well as CPA, MPA, and GnRH agonists, it takes weeks, 4,5 children) on the one side and sometimes months, before an effect is seen. Nevertheless, the criminal offense of child the use of SSRIs, with their relatively low adverse effect pro- Related article page 897 sexual abuse on the other. file, and the results on GnRH agonists were important ear- Most child sexual abuse offenses are not committed in rela- lier milestones, but without RCTs. tion to a pedophilic disorder. However, for people who have The author of this Editorial, together with an interdisci- already committed a child abuse offense, pedophilic interest plinary team and the support of the pharmaceutical industry 1 7 is a significant risk factor for reoffending. over some years, had very carefully prepared an RCT http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

A Randomized Clinical Trial in Patients With a Pedophilic Disorder

Briken, Peer
JAMA Psychiatry , Volume 77 (9) – Sep 29, 2020
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/a-randomized-clinical-trial-in-patients-with-a-pedophilic-disorder-TAuZN7gAFb
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2020.0430
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL A Milestone Peer Briken, MD Nowadays, experts distinguish very clearly between pedo- terone (MPA) acetate is an option. For the high-risk groups, philic disorder as a psychiatric disorder (characterized by gonadotropin-releasing hormone (GnRH) agonists, such as leu- prolide, have been in use for more than 20 years. However, for intense sexual interest in children accompanied by distress, interpersonal difficulty, and/or a risk of sexual offenses against SSRIs as well as CPA, MPA, and GnRH agonists, it takes weeks, 4,5 children) on the one side and sometimes months, before an effect is seen. Nevertheless, the criminal offense of child the use of SSRIs, with their relatively low adverse effect pro- Related article page 897 sexual abuse on the other. file, and the results on GnRH agonists were important ear- Most child sexual abuse offenses are not committed in rela- lier milestones, but without RCTs. tion to a pedophilic disorder. However, for people who have The author of this Editorial, together with an interdisci- already committed a child abuse offense, pedophilic interest plinary team and the support of the pharmaceutical industry 1 7 is a significant risk factor for reoffending. over some years, had very carefully prepared an RCT

Journal

JAMA Psychiatry – American Medical Association

Published: Sep 29, 2020

References

  • The Screening Scale for Pedophilic Interests (SSPI): construct, predictive, and incremental validity
    Helmus, L; Ó Ciardha, C; Seto, MC
  • Preventing sexual abusers of children from reoffending: systematic review of medical and psychological interventions
    Långström, N; Enebrink, P; Laurén, EM; Lindblom, J; Werkö, S; Hanson, RK
  • Effect of gonadotropin-releasing hormone antagonist on risk of committing child sexual abuse in men with pedophilic disorder: a randomized clinical trial
    Landgren, V; Malki, K; Bottai, M; Arver, S; Rahm, C
  • The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias
    Thibaut, F; De La Barra, F; Gordon, H; Cosyns, P; Bradford, JM
  • Treatment of paraphilic disorders in sexual offenders or men with a risk of sexual offending with luteinizing hormone-releasing hormone agonists: an updated systematic review
    Turner, D; Briken, P
  • Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone
    Rösler, A; Witztum, E
  • Double-blind, controlled, clinical trial planned in germany to investigate the efficacy of psychotherapy combined with triptorelin in adult male patients with severe pedophilic disorders: presentation of the study protocol
    Briken, P; Berner, W
  • Which factors influence the appropriateness of testosterone-lowering medications for sex offenders? a survey among clinicians from German forensic-psychiatric institutions
    Turner, D; Basdekis-Jozsa, R; Dekker, A; Briken, P
  • Failure of a study in forensic psychiatric hospitals : clinical trial to investigate the additive effect of triptorelin on the efficacy of psychotherapy
    Briken, P; Müller, JL; Berner, W
  • Measuring pedophilic sexual interest
    Carvalho, J; Bradford, J; Murphy, L; Briken, P; Fedoroff, P